Judd Berman

This inventor holds 7 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 5 EPO patents. Top assignees: Affinium Pharmaceuticals, Inc., Bikam Pharmaceuticals Inc.. Active years: 2009-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Judd Berman. Retrieved from https://idiyas.com/inventor/judd-berman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 8)

% Patents Active = 42.9

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 32(Granted Patents)

Company Filing History:

4 out of 33

Affinium Pharmaceuticals, Inc.

patents

3 out of 7

Bikam Pharmaceuticals Inc.

patents

Years Active: 2009-2018

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10040749 - Opsin-binding ligands, compositions and methods of use (2018-08-07),

2. 9562022 - Opsin-binding ligands, compositions and methods of use (2017-02-07),

3. 9499464 - Opsin-binding ligands, compositions and methods of use (2016-11-22),

4. 8450307 - Therapeutic agents, and methods of making and using the same (2013-05-28),

5. 7879872 - Compositions comprising multiple bioactive agents, and methods of using the same (2011-02-01),

6. 7790709 - Heterocyclic compounds, methods of making them and their use in therapy (2010-09-07),

7. 7601526 - [object Object] (2009-10-13),

Title: The Innovative Contributions of Judd Berman

Introduction

Judd Berman is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of ophthalmology through his innovative research and development of therapeutic compounds. With a total of seven patents to his name, Berman's work focuses on addressing critical eye conditions.

Latest Patents

Berman's latest patents include groundbreaking work on opsin-binding ligands, compositions, and methods of use. These compounds are designed to treat ophthalmic conditions caused by the accumulation of toxic visual cycle products in the eye, such as dry adult macular degeneration. His patents also address issues related to the misfolding of mutant opsin proteins and the mis-localization of opsin proteins. The compositions he has developed can be used alone or in combination with other therapeutic agents, providing a comprehensive approach to treatment. Additionally, methods for synthesizing these agents are disclosed, further enhancing their potential applications.

Career Highlights

Throughout his career, Judd Berman has worked with various companies, including Affinium Pharmaceuticals, Inc. and Bikam Pharmaceuticals Inc. His experience in these organizations has allowed him to refine his expertise in developing innovative solutions for complex medical challenges.

Collaborations

Berman has collaborated with notable professionals in his field, including David S. Garvey and Tan Quach. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Judd Berman's contributions to ophthalmology through his innovative patents and collaborations highlight his commitment to improving eye health. His work continues to pave the way for new therapeutic options in treating serious eye conditions.

Profile summary based on public USPTO records.